1. Clinical & Scientific Overview
Sulfasalazine (TIP-MED-000302, Reference Code [5.22]-C32) is classified under
Gastrointestinal & Hepatobiliary Medicines (Ch 05) as a Colonic Topical Anti-Inflammatory Salicylate & Disease-Modifying Antirheumatic Prodrug (Schedule H | NLEM 2022).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Co-indexed constituent under primary monograph [5.22] (Mesalazine (5-Aminosalicylic Acid — 5-ASA) & Sulfasalazine). Representative Indian Market Examples (Edition 2.7 Ch 05 [5.22], p. 70): Mesalazine: Mesacol / Mesacol OD (Sun), Pentasa (Ferring), Vegaz OD. Sulfasalazine: Saaz / Saaz DS (Ipca), Salazar — Strengths & Dosage Forms: Mesalazine Delayed/Extended-Release Tablets: 400 mg, 800 mg, 1200 mg (1.2 g OD); Suppositories: 500 mg, 1 g. Sulfasalazine Enteric-Coated Tablets: 500 mg, 1000 mg (DS)
Mesalazine Delayed/Extended-Release Tablets: 400 mg, 800 mg, 1200 mg (1.2 g OD); Suppositories: 500 mg, 1 g. Sulfasalazine Enteric-Coated Tablets: 500 mg, 1000 mg (DS)
3. Mechanism of Action & Pharmacodynamics
Colonic Topical Anti-Inflammatory Salicylate & Disease-Modifying Antirheumatic Prodrug (Schedule H | NLEM 2022) acting on target receptor/enzyme pathways in Gastrointestinal & Hepatobiliary Medicines (Ch 05): clinical efficacy is mediated via Colonic Topical Anti-Inflammatory Salicylate & Disease-Modifying Antirheumatic Prodrug (Schedule H | NLEM 2022) for Mesalazine: Induction and maintenance of remission in mild-to-moderate Ulcerative Colitis. Sulfasalazine: Ulcerative Colitis, Crohn's colitis, and Rheumatoid Arthritis / Peripheral Spondyloarthritis (DMARD).
4. Therapeutic Indications & Evidence-Supported Uses
- Mesalazine: Induction and maintenance of remission in mild-to-moderate Ulcerative Colitis
- Sulfasalazine: Ulcerative Colitis, Crohn's colitis, and Rheumatoid Arthritis / Peripheral Spondyloarthritis (DMARD)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Mesalazine: Active UC: 2.4–4.8 g/day PO; Maintenance: 1.2–2.4 g/day PO. Sulfasalazine (RA): Start 500 mg PO OD–BD, increase weekly by 500 mg to 1000 mg (1 g) BD–TDS (Max 3 g/day)
Administration & Meal Timing: Swallow Mesalazine PR/OD and Sulfasalazine EC tablets WHOLE with a full glass of water after meals — NEVER crush, chew, or break the pH-dependent enteric coating! | Once Daily (1.2 g MMX/OD Mesalazine with breakfast) or BD/TDS after meals
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Follows class pharmacokinetic profile detailed in parent monograph [5.22].
Renal: Check eGFR/SCr before starting, every 3 months for the first year, and every 6 months thereafter; CONTRAINDICATED if eGFR <30 mL/min! Hepatic: Avoid in severe liver disease
Renal: Check eGFR/SCr before starting, every 3 months for the first year, and every 6 months thereafter; CONTRAINDICATED if eGFR <30 mL/min! Hepatic: Avoid in severe liver disease
Renal: Check eGFR/SCr before starting, every 3 months for the first year, and every 6 months thereafter; CONTRAINDICATED if eGFR <30 mL/min! Hepatic: Avoid in severe liver disease
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated in severe renal or hepatic impairment, salicylate hypersensitivity, and (for Sulfasalazine) sulfa allergy, G6PD deficiency, or porphyria
Key Clinical Precautions: Renal: Check eGFR/SCr before starting, every 3 months for the first year, and every 6 months thereafter; CONTRAINDICATED if eGFR <30 mL/min! Hepatic: Avoid in severe liver disease
8. Adverse Effects Profile
- Mesalazine: Mild headache, nausea, abdominal pain. Sulfasalazine: Nausea, headache, orange-yellow discolouration of urine/tears/sweat, reversible oligospermia
- Interstitial nephritis (5-ASA nephrotoxicity — check serum creatinine!), pancreatitis, pericarditis/myocarditis, agranulocytosis/aplastic anaemia, SJS/TEN or DRESS syndrome (Sulfasalazine)
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- 5-ASA and Sulfasalazine inhibit TPMT enzyme -> markedly increase bone-marrow toxicity (pancytopenia) of Azathioprine / 6-Mercaptopurine! Sulfasalazine impairs Folic Acid absorption (supplement Folic Acid 5 mg!) and reduces Digoxin absorption
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [5.22].
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Swallow tablets whole (intact ghost shells in stool are normal); on Sulfasalazine (Saaz), orange-yellow urine/tears are harmless, drink plenty of water, take Folic Acid supplement, and get an urgent blood count if fever, sore throat, or skin rash occurs
- Meal & Clock Timing Instruction: Swallow Mesalazine PR/OD and Sulfasalazine EC tablets WHOLE with a full glass of water after meals — NEVER crush, chew, or break the pH-dependent enteric coating! (Once Daily (1.2 g MMX/OD Mesalazine with breakfast) or BD/TDS after meals)
- Missed Dose Protocol: Take with next meal if remembered; never crush delayed-release tablets
- Geriatric Dispensing Pearl: Monitor renal function (eGFR) closely in older adults on chronic 5-ASA therapy
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Mesalazine Delayed/Extended-Release Tablets: 400 mg, 800 mg, 1200 mg (1.2 g OD); Suppositories: 500 mg, 1 g. Sulfasalazine Enteric-Coated Tablets: 500 mg, 1000 mg (DS)
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [5.6] Domperidone — Peripheral Dopamine D2-Receptor Antagonist; Gastroprokinetic & An
- [5.7] Ondansetron — Selective Serotonin 5-HT3 Receptor Antagonist; Central & Peripher
- [5.8] Lactulose — Synthetic Non-Absorbable Disaccharide (Galactose-Fructose); Osmot
- [5.9] Bisacodyl — Diphenylmethane Stimulant Laxative (Colonic Myenteric Plexus Stim
